Promentis Pharmaceuticals
Promentis Pharmaceuticals, Inc. is a privately-held biopharmaceutical company dedicated to developing innovative therapies for neuropsychiatric disorders. The company's mission is to redefine what is possible in the treatment of CNS conditions by focusing on unique targets such as System xc- to address glutamatergic imbalance and oxidative stress. Their first indication is trichotillomania, a disorder with no approved therapy, and they aim to advance their compounds into clinical trials to provide new treatment options.
Industries
Nr. of Employees
small (1-50)
Promentis Pharmaceuticals
826 N. Plankinton Ave., Suite 400, Milwaukee, WI 53203
Patents
Ethyl (2R)-2-acetamido-3-(4-methylbenzoylsulfanyl)propanoate and uses thereof
US-9012674-B1
View Details
Ethyl (2R)-2-acetamido-3-(4-methylbenzoylsulfanyl)propanoate and uses thereof
US-9012674-B1
View DetailsProducts
Clinical-stage oral small-molecule activators of System xc-
A development program of oral small-molecule compounds that activate the System xc- antiporter to modulate glutamatergic signaling and oxidative stress for treatment of impulse control and other neuropsychiatric disorders.
Clinical-stage oral small-molecule activators of System xc-
A development program of oral small-molecule compounds that activate the System xc- antiporter to modulate glutamatergic signaling and oxidative stress for treatment of impulse control and other neuropsychiatric disorders.
Expertise Areas
- CNS drug discovery and development
- Medicinal chemistry for small molecules
- Glutamatergic-targeted therapeutics (System xc- modulation)
- Clinical trial design and management (Phase 1–2)
Key Technologies
- Activation of System xc- (cystine–glutamate antiporter)
- Oral small-molecule therapeutics
- Glutamatergic modulation and oxidative stress targeting
- Single ascending dose (SAD) and multiple ascending dose (MAD) clinical designs
News & Updates
Senior Vice President of R&D, Dr. Chad Beyer, will present nonclinical data and initial clinical findings of SXC-2023, the company’s first-in-class activator of System xc-, at the ACNP meeting in Hollywood, Florida.
Promentis Pharmaceuticals announced that Dr. Chad Beyer and Michael Neary will present key scientific data on SXC-2023 at the Society for Neuroscience meeting in San Diego, California.
Dr. Chad E. Beyer will present psychometric findings from the first-ever, multi-center trial conducted in patients with trichotillomania.
Dr. Chad Beyer will present clinical findings from the company’s Phase 2A study in trichotillomania.
The Phase 2A behavioral biomarker study showed significant improvements in impulse control, and the Phase 2 multi-center study in trichotillomania is fully enrolled.
Phase 1 studies demonstrated that SXC-2023 is safe and well-tolerated over a wide dose range in healthy volunteers.
Senior Vice President of R&D, Dr. Chad Beyer, will present nonclinical data and initial clinical findings of SXC-2023, the company’s first-in-class activator of System xc-, at the ACNP meeting in Hollywood, Florida.
Promentis Pharmaceuticals announced that Dr. Chad Beyer and Michael Neary will present key scientific data on SXC-2023 at the Society for Neuroscience meeting in San Diego, California.
Dr. Chad E. Beyer will present psychometric findings from the first-ever, multi-center trial conducted in patients with trichotillomania.
Dr. Chad Beyer will present clinical findings from the company’s Phase 2A study in trichotillomania.
The Phase 2A behavioral biomarker study showed significant improvements in impulse control, and the Phase 2 multi-center study in trichotillomania is fully enrolled.
Phase 1 studies demonstrated that SXC-2023 is safe and well-tolerated over a wide dose range in healthy volunteers.